According to media reports, Danish pharmaceutical giant Novo Nordisk is negotiating an innovative pricing agreement for its weight loss drug Wegovy with healthcare systems in some countries. The company hopes to help medical service institutions allocate costs over the years through agreements, thereby expanding Wegovy's market share.